Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Inhibrx Biosciences Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 4 distinct art units, showing broad examiner distribution within a somewhat more concentrated art-unit structure.
CHEONG, CHEOM-GIL is the busiest examiner, with 1 pending matter. No examiner dominates the open work, so counsel should maintain separate response strategies while monitoring whether related biotechnology issues recur across the art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18520308 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | EDGINGTONGIORDANO, FRANCESCA | 66d overdue |
| 18969101 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME | CHEONG, CHEOM-GIL | — |
| 18792984 | CD33-Binding Polypeptides and Uses Thereof | ROONEY, NORA MAUREEN | — |
| 18520308 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1645 | 1 |
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18969101 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME | CHEONG, CHEOM-GIL | 1645 | §103§112DP | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18792984 | CD33-Binding Polypeptides and Uses Thereof | ROONEY, NORA MAUREEN | 1641 | §112Other | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18520308 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | CESARE, JOSEPH DAVID | 1675 | §112Other | Non-Final OA | 5d | Pending | Aug 07, 2023 |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103Other | Non-Final OA | 66d overdue | Pending | Jun 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInhibrx Biosciences Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Cheom-Gil Cheong has the most, with 1 of Inhibrx Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
